tirzepatide injection site reaction treatment reactions after long-term subcutaneous delivery of drisapersen: a retrospective study | European Journal of Pediatrics Tirzepatide Injection Site Reaction Treatment:

Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment

This is the lens through which we view every product we create

How peptide therapy works at Peak Performance We treat peptides as medicine, which means a real workup, real oversight, and a plan that is reviewed over time

Supportive strategies: Prioritize nutrient-rich, minimally processed meals (veg, fruits, whole grains, legumes, lean proteins, nuts, seeds) and fluids so that the foundation of their diet is nutritionally adequate

Neither the European Food Safety Authority (EFSA) nor the GB Nutrition and Health Claims Register has approved any health claims for berberine related to weight management, reflecting the current insufficiency of evidence